InteRNA Inks Sponsored-Research Deal with Dana Farber for miRNA Cancer Rx Discovery

Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.